Drug Discovery Service

Dr. Ismail Moarefi, Chief Scientific Officer of CRELUX in Martinsried, Germany

"Together with Nanotemper Technologies we have optimized microscale thermophoresis for fragment screening applications which are difficult to access with standard technologies. Access to accurate information on fragment Kd, binding mode and aggregation behaviour of compounds enable informed decision making. Together with a proprietary fragment collection, this technology forms now the core of the CRELUX fragment based drug discovery service offerings. "

Dr. Ismail Moarefi